Navigation Links
The Genesis of Gendicine: The Story Behind the First Gene Therapy


In this BioPharm International exclusive interview,SiBionos founder relates the science and manufacture of his companys innovative cancer therapy.



Dr.Zhaohui Peng is the chairman,chief executive officer, and founder of Shenzhen SiBiono GeneTech Co., Ltd.,
Langshen Road, Shenzhen Hi-Tech Industrial Park, Shenzhen, China,
0755.2696.8818,
fax: 0755.2696.8808,
sbn@sibiono.com;www.sibiono.com


In October 2003, Shenzhen SiBiono GeneTech made history by becoming the first company approved to market a gene therapy medication. Chinas State Food and Drug Administration (SFDA) approved Gendicine for treatment of head and neck squamous cell carcinoma (HNSCC). SiBiono believes that continued clinical trials will prove Gendicine to be effective as a widespectrum anticancer agent.

In March, BioPharm International interviewed Dr. Zhaohui Peng, SiBiono's founder, chairman, and CEO, to learn more about the science behind gene therapy, the clinical experience with Gendicine, and the processes involved in manufacturing this ground-breaking new therapy. In addition to a distinguished academic career, Dr. Peng served as director of a research institute at The First Medical University in Guangzhou and as a visiting professor at both the University of Chiba in Japan and the University of California. He also conducted research at two US biotech companies. Dr. Peng has devoted more than ten years to gene therapy research, development, and commercialization.


GENE THERAPY BASICS
BPI: You have used the term adenoviral vector +p53 tumor suppressor-gene delivery system. Will you briefly describe the science
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Automation of TempliPhi and GenomiPhi DNA Amplification Kits on the Genesis Freedom Robotic Sample Processor
2. RNAi: Get the Whole Story
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Genesis Gendicine The Story Behind the First Gene Therapy

(Date:5/23/2013)... , May 23, 2013 VG Energy, ... alliance with DAK Renewable Research to conduct field ... yield. VG Energy is a majority owned subsidiary ... VG Energy,s exclusively licensed compound LipidMax ... oil yield in plants, possessing a wide variety ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... 2013 On April 19th the ... to search for the growing antibiotic resistant bacteria that ... a year long study were released late last month ... meats, over previous years. For those suffering from bacteria ... antibiotic resistant bacteria in food, may eventually help breed ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... Market, According to a ... New Report from Decision Resources, WALTHAM, Mass., Oct. 17 ... that Merck,will obtain blockbuster antidiabetic drug sales in the type 2 ... will see rapid uptake as a second-and third-line agent in type ...
... Kyphon Inc.,(Nasdaq: KYPH ) announced today that its ... Inc. (NYSE: MDT ) at a special,meeting of ... 26, 2007, Kyphon entered into a,definitive merger agreement with ... the outstanding shares of Kyphon common stock for,$71.00 per ...
... LAWRENCE, Mass., Oct. 16 NxStage Medical,Inc. (Nasdaq: ... plans to release its financial results for the third,quarter ... of the,financial markets. NxStage will also host a ... 2007 to discuss its third quarter 2007 financial results. ...
Cached Biology Technology:Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Kyphon Stockholders Approve Merger with Medtronic 2NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2
(Date:5/24/2013)... in one French Quarter neighborhood of New Orleans to ... Annette Hurley, PhD, Assistant Professor of Audiology at LSU ... third-year LSUHSC doctor of audiology student, recommend that people ... Their case study is published online in the current ... "An important part of an audiologist,s practice is aiding ...
(Date:5/24/2013)... the search for medication against Alzheimer,s disease, scientists have focused ... down Amyloid beta (A-beta). After all, it is the accumulation ... of Alzheimer,s patients. Starting point for the formation of A-beta ... the first to unravel the function of APPL the ... fruit flies. , Alessia Soldano (VIB/KU Leuven): "We have ...
(Date:5/24/2013)... A conference of 500 leading water scientists from around ... major reforms, "in the short span of one or ... on Earth will be living under the handicap of ... resource for which there is no substitute. This handicap ... , The scientists bluntly pointed to chronic underlying problems ...
Breaking Biology News(10 mins):Please do try this at home 2A new strategy required in the search for Alzheimer's drugs? 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4
... ?a region in the brain linked to emotion and feelings ... the Jan. 26 issue of the journal Science. , The ... , It also raises the possibility that other ... circuits for pleasure. , The senior authors of the ...
... could help control weight, lower fat and cholesterol levels, and ... Chemistry & Industry, the magazine of the SCI. , Yellow ... this is one of the reasons why frozen food manufacturer ... a team of Korean researchers has shown that black soya ...
... with more than a decade’s worth of statistics, researchers are ... gay and bisexual men. , The overall number of syphilis ... to just 7,177 in 2003 perhaps because of a nationwide ... their rates rise significantly in this decade. , ...
Cached Biology News:Smokers quit after damage to brain region 2Syphilis rate on rise in US gay, bisexual men 2
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
... RED Chromogen System consists of ... buffer. FAST RED reacts in ... to produce red staining with ... The FAST RED tablets ...
Mouse Cell Line Slides...
Biology Products: